antibody-dependent cellular cytotoxicity
| 6 min read
As deep B cell depletion moves into autoimmune disease, antibody-directed allogeneic NK cell therapy may offer a different path to potency, scalability, and outpatient treatment.
| 4 min read
Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need.
Available on Demand
Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.
Page 1 of 1 - 3 Total Items
